EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Clinical pharmacokinetic characteristics of Jaktinib in subjects with hepatic impairment in a phase I trial

Manna Zhao, Hua Zhang, Sheng Ma, Shuqing Gong, Cheng Wei, Liyan Miao, Weifeng Zhao

Drug Metabolism and Pharmacokinetics · 2024

DOI: 10.1016/j.dmpk.2024.101030 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Drug Metabolism and Pharmacokinetics, 2024. Verfasst von Manna Zhao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, 215006, PR China. Electronic addres…. Hauptthemen laut MEDLINE: Liver Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Jaktinib is a novel Janus kinase (JAK) inhibitor, and a phase I clinical trial of single-dose Jaktinib was conducted in a population of subjects with hepatic impairment to assess the safety, tolerability, and pharmacokinetic characteristics of Jaktinib. The patients were administered orally with 100 mg Jaktinib on day 1 in all the mild hepatic impairment group (mild group, n = 8), moderate hepatic impairment group (moderate group, n = 8) and normal hepatic function group (normal group, n = 8), and the blood samples were collected for later analysis. The mild to moderate hepatic impairment affected the metabolism of Jaktinib, which may lead to accumulation of original Jaktinib. The pharmacokinetic characteristics of the metabolites (ZG0244 and ZG0245) of Jaktinib were also analyzed. The exposure of Jaktinib is approximately 2-fold in patients with mild and moderate hepatic impairment than normal hepatic function. No serious adverse events occurred. In summary, a dosage reduction is recommended for patients with mild or moderate hepatic impairment. Further investigations for the dose adjustment in mild/moderate hepatic impairment will be considered. Trial registration number: NCT04993404.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver DiseasesHumansMaleMiddle AgedFemaleAdultAgedAdministration, OralJanus Kinase Inhibitors

Stichwörter der Autor:innen

Hepatic impairmentJaktinibPharmacokinetic characteristicsPhase I trialSafety

Substanzen

Janus Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, 215006, PR China. Electronic address: zhaomana2021@163.com.
  • Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, 215006, PR China. Electronic address: huazhang@wust.edu.cn.
  • Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, 215006, PR China. Electronic address: masheng@suad.edu.cn.
  • Department of Zelgen Medicine and Writing, Suzhou Zelgen Biopharmaceutical Co., Ltd, Suzhou, Jiangsu Province, 215000, PR China. Electronic address: gongsq@zelgen.com.
  • Project Department, Suzhou Zelgen Biopharmaceutical Co., Ltd, Suzhou, Jiangsu Province, 215000, PR China. Electronic address: weic@zelgen.com.
  • Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, 215006, PR China. Electronic address: miaoliyan@suda.edu.cn.

Zitieren

APA

Zhao, M., Zhang, H., Ma, S., Gong, S., Wei, C., Miao, L., & Zhao, W. (2024). Clinical pharmacokinetic characteristics of Jaktinib in subjects with hepatic impairment in a phase I trial. Drug Metabolism and Pharmacokinetics. https://doi.org/10.1016/j.dmpk.2024.101030

Vancouver

Zhao M, Zhang H, Ma S, Gong S, Wei C, Miao L, et al. Clinical pharmacokinetic characteristics of Jaktinib in subjects with hepatic impairment in a phase I trial. Drug Metabolism and Pharmacokinetics. 2024. doi:10.1016/j.dmpk.2024.101030

BibTeX
@article{Zhao2024,
  author = {Zhao, Manna and Zhang, Hua and Ma, Sheng and Gong, Shuqing and Wei, Cheng and Miao, Liyan and Zhao, Weifeng},
  title = {Clinical pharmacokinetic characteristics of Jaktinib in subjects with hepatic impairment in a phase I trial},
  journal = {Drug Metabolism and Pharmacokinetics},
  year = {2024},
  doi = {10.1016/j.dmpk.2024.101030}
}
Kostenlos starten →